NXI-S172

NXI-S172 is a preclinical-stage antibody-drug conjugate (ADC) being developed by NEX-I for the treatment of solid tumors. Discovered using the company's proprietary SMRT (Screening for Mechanisms of Resistance to Therapy) platform, NXI-S172 targets a specific tumor surface epitope associated with immunosuppressive and standard-of-care (SoC)-resistant tumor microenvironments. By targeting these epitopes, the drug aims to overcome resistance mechanisms that limit the efficacy of current cancer therapies. As an ADC, it likely consists of a monoclonal antibody conjugated to a cytotoxic payload, though specific details regarding the linker and payload have not been publicly disclosed.